Zyoxel, an expert in advanced in vitro 3D liver models for drug discovery and drug testing, has today announced it is changing its name to CN Bio Innovations Ltd (CNBIO). The move is part of a strategic rebrand designed to closer align the organisation with its Hong Kong-based holding company, CN Innovations Holdings Limited (CNI).
“Since our founding in 2009, we have enjoyed a productive relationship with CNI, benefiting from their extensive and diverse business experience under the leadership of Company Director and CNI Managing Director, Mr Charles Chong” said Maureen Coleman, Chairman of CNBIO. “The name change ensures that we are more effectively aligned with the brand of our holding company and clarifies our status as an integral part of the CNI family. It also reflects the increasing confidence and commitment of our principal shareholder, and signifies the start of an exciting new phase in CNBIO’s development.”Press releases